Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2/PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is for people who have been diagnosed with chronic hepatitis C, specifically those who have a certain type of the virus, genotype 1, and who have not yet received treatment for hepatitis C. This pilot study is designed to test whether the addition of vitamin D, to the three drugs (Incivek (telaprevir), Pegasys (peginterferon alfa-2a), and ribavirin) that are approved by the Food and Drug Administration (FDA) for the treatment of hepatitis C, can help eliminate the HCV from the body. Currently, doctors are unsure if the addition of vitamin D to prescribed hepatitis C therapy will have any effects on how the body clears the virus.

Once enrolled, participants will be randomly assigned (like flipping a coin) to receive telaprevir + peginterferon alfa-2a + ribavirin + vitamin D3 (treatment group) or telaprevir + peginterferon alfa-2a + ribavirin (control group). A total of 80 participants, of all races/ethnicities, will be included in this study, at 5 to 10 VA hospital study sites (10 - 20 participants/site).

Participants assigned to the treatment group will begin a lead-in phase where they will receive 5,000 IU of vitamin D3 per day. Every two weeks during the lead-in phase, participants will be tested to determine the Vitamin D level in their blood, as well as other tests, including HCV RNA (to determine the amount of virus present) and calcium levels. Once an adequate level of Vitamin D is detected in participants' blood, participants will begin treatment with telaprevir + peginterferon alfa-2a + ribavirin + vitamin D3 (15,000 IU/week) for 12 weeks.

Participants randomized to the control group will immediately begin treatment with telaprevir + peginterferon alfa-2a + ribavirin for 12 weeks. At the end of Week 12 the participants' involvement in the study will be complete.

Adverse events and effects of vitamin D3 will be obtained by assessing participants' medical history, physical examination, and blood tests at clinic visits. HCV RNA will be assessed at Screening, Day 1, Week 2, 4, 8 and 12.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?

NCT01151397

Chronic Hepatitis C

UNKNOWN NA

Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients

NCT01439776

Chronic Hepatitis C

COMPLETED PHASE4

Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders

NCT01226446

Chronic Hepatitis C

COMPLETED PHASE2

Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?

NCT01146626

Hepatitis C

UNKNOWN NA

Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c

NCT01655966

Chronic Hepatitis c

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VitD+telaprevir+peginterferon+ribavirin

Participants randomized to the treatment group will receive 5,000IU/day of vitamin D3 during the lead-in phase. When the serum 25(OH)D level is ≥35ng/ml the participant will begin telaprevir + vitamin D3 (15,000IU/week) + peginterferon alfa-2a (180ug/week) + weight based ribavirin treatment.

Group Type ACTIVE_COMPARATOR

Telaprevir

Intervention Type DRUG

Peginterferon alfa-2a

Intervention Type DRUG

Ribavirin

Intervention Type DRUG

Vitamin D

Intervention Type DIETARY_SUPPLEMENT

Telaprevir + Peginterferon + Ribavirin

Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.

Group Type ACTIVE_COMPARATOR

Telaprevir

Intervention Type DRUG

Peginterferon alfa-2a

Intervention Type DRUG

Ribavirin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telaprevir

Intervention Type DRUG

Peginterferon alfa-2a

Intervention Type DRUG

Ribavirin

Intervention Type DRUG

Vitamin D

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Incivek Pegasys

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic Hepatitis C genotype 1 infection
* Treatment naïve
* Age \>18 years
* Agree to genetic testing

Exclusion Criteria

* Liver disease other than from hepatitis C
* HCV infection with mixed genotypes
* Decompensated liver disease
* AFP\>100ng/ml.
* Known HIV infection
* Serum 25(OH)D less than 12ng/ml or greater than 30ng/ml
* Regular vitamin D supplement use
* Regular calcium supplement use
* Refusal to abstain from vitamin D supplementation
* Current or past history of kidney stones
* Current use of any of the prohibited medications listed in section 5.5 and the INCIVEK® package insert.
* Need for therapeutic vitamin D or calcium (e.g. treatment for osteoporosis, osteomalacia, hyperparathyroidism etc.), in the opinion of the investigator
* Significant substance abuse within the past 6 months,
* Suicidal attempt in the past 10 years or suicidal ideation in past 3 months, or any other psychiatric condition that the investigator deems would make a subject unsuited for treatment with peginterferon or ribavirin.
* Confirmed or suspected malignancy, or history of malignancy within the past 3 years (except treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix)
* Any autoimmune disease not easily controlled (in the opinion of the investigator)
* Any condition resulting in malabsorption (
* Poorly controlled thyroid disorder, or diabetes mellitus (HbA1c \> 9)
* Glomerular diseases (e.g., glomerulosclerosis or glomerulonephritis) associated with a serum creatinine \>1.5 times the upper limit of normal
* Current or history of any clinically significant cardiac abnormalities/dysfunction (eg, angina, congestive heart failure, myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, significant arrhythmia) including current uncontrolled hypertension or history of use of antianginal agents for cardiac conditions (Inclusion will be considered if clearance by a cardiologist is obtained.)
* Receipt of an investigational drug within the past 30 days
* Females who have a positive pregnancy test at the time of screening, are breastfeeding or who anticipate pregnancy within the next 18 months, or men with pregnant partners
* Lack of agreement from subject to use two forms of acceptable contraception
* History or other evidence of any significant illness which, in the opinion of the investigator, would make the patient, unsuitable for the study
* Laboratory Exclusions

Hemoglobin: \<12gm/dl male or female

Neutrophil: \<1,200/mm3

Platelets: \<90,000/mm3

INR: \>1.5

Albumin: \<3.2gm/dl

Total Bilirubin: \>2.0mg/dl

HbA1c: \>9.5%

Serum Creatinine: \>1.5 times the upper limit of normal

Serum Calcium Within local laboratory normal range

Parathyroid hormone (PTH) \<10 or \>55 pg/mL

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No